SHARPE
Reported results
- Net revenues were $6.1 million compared with $6.9 million in the prior-year period, a decrease of 11.2% (GAAP)
- Gross profit was $5.0 million, or 82.6% of sales, compared with $4.6 million, or 67.6% of sales; excluding a non-recurring $0.55 million IEEPA customs duty refund benefit, gross margin was approximately 73.6% (GAAP)
- Income from operations was $437,000 compared with $412,000 in the prior-year period (GAAP)
- Net income was $0.4 million, or $0.05 per diluted share, compared with $0.3 million, or $0.04 per diluted share (GAAP)
- Adjusted EBITDA was $0.8 million compared with $0.7 million (non-GAAP); Adjusted EBITDA as a percentage of revenues was 13.6% compared with 9.8% (non-GAAP)
- Net cash provided by operating activities was $3.8 million compared with $739,000 used in the prior-year period (GAAP); cash balance was $7.9 million as of August 31, 2026 with no outstanding borrowings
Guidance
- XCOR II initial orders exceeded $3.6 million as of September 30, 2026; shipments are underway in the second quarter of fiscal 2027
- Company anticipates advertising costs of approximately $360,000 and inventory staging related to XCOR II launch that did not benefit first-quarter revenue will convert to revenue in the second quarter
Notes
First quarter includes non-recurring $0.55 million IEEPA customs duty refund recognized as reduction of cost of revenues; $0.32 million of IEEPA refunds related to products in inventory recorded as inventory reduction; $0.04 million of IEEPA refund interest included in other income. Company brought three strategic partners into Reviv3 ProCare Company receiving approximately 25% ownership interest in aggregate; AXIL retains approximately 75% and consolidates Reviv3 results; shares valued at $137,511 recorded as non-cash expense. No IEEPA refund claims remain outstanding.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-06 (8-K, Item 2.02). Read the original filing on sec.gov.